Foreign Filer Report • Apr 26, 2024
Preview not available for this file type.
Download Source File6-K 1 f6k_042624.htm FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____
FORM 6-K
____
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 26, 2024
____
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
____
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
Field: Page; Sequence: 1
Field: /Page
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo Nordisk A/S as per the end of a month where changes therein have occurred.
Referring to Company Announcement no 32/2024 dated 24 April 2024, please find below a statement regarding the total number of voting rights and share capital in Novo Nordisk A/S as per 26 April 2024.
| | Number
of shares (of
DKK 0.10 each) | Share
capital (nominal value,
DKK) | Number
of votes 1 |
| --- | --- | --- | --- |
| A
shares | 1,074,872,000 | 107,487,200 | 107,487,200,000 |
| B
shares | 3,390,128,000 | 339,012,800 | 33,901,280,000 |
| Total | 4,465,000,000 | 446,500,000 | 141,388,480,000 |
1 Each A share of DKK 0.01 carries 10 votes, whereas each B share of DKK 0.01 carries one vote. Thus, each A share of DKK 0.10 carries 100 votes and each B share of DKK 0.10 (the present denomination of the company's shares) carries 10 votes. Treasury shares are included in the table above but voting rights of treasury shares are suspended at the general meetings of Novo Nordisk A/S.
Field: Page; Sequence: 2
Field: /Page
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, v isit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contact for further information.
| Media: | |
|---|---|
| Ambre James-Brown +45 3079 9289 [email protected] | Liz Skrbkova (US) +1 609 917 0632 [email protected] |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 [email protected] | Jacob Martin Wiborg Rode +45 3075 5956 [email protected] |
| David Heiberg Landsted +45 3077 6915 [email protected] | Mark Joseph Root (US) +1 848 213 3219 [email protected] |
| Sina Meyer +45 3079 6656 [email protected] | Frederik Taylor Pitter +45 3075 8259 [email protected] |
| Novo Nordisk A/S Investor Relations |
|---|
| Company |
| announcement No 33 / 2024 |
Field: Page; Sequence: 4
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: April 26, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer
Field: Rule-Page
Field: /Rule-Page
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.